Evaluation of the efficacy of hydrocyn™ aqua in comparison to commercially available super oxidized solution as dressing solution for diabetic foot ulcers
Introduction: Diabetic patients will have a 15% of risk of developing diabetic foot ulcers during the disease course and usually this is complicated by infections. The principle aim of treatment is to promote wound healing combining surgical and non-surgical treatment. Disinfectants have been us...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2016
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/42504/1/Dr._Mohd_Shaharil_Abdul_Aziz-24_pages.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction:
Diabetic patients will have a 15% of risk of developing diabetic foot ulcers during the disease
course and usually this is complicated by infections. The principle aim of treatment is to
promote wound healing combining surgical and non-surgical treatment. Disinfectants have
been used traditionally but it has the argument of cyto-toxicity against host. Hydrocyn™
Aqua is an antiseptic solution in the form of stable super oxidized solution with neutral pH
and longer shelf life which can be used in the treatment of diabetic foot ulcers.
Objective:
The objective of this study is to compare the efficacy of Hydrocyn™ Aqua with the
commercially available super oxidized solution (CASOS) in term of wound size reduction
and optimal wound bed preparation.
Methodology:
This was a prospective, single-blinded randomized controlled trial involving patients with
diabetes mellitus, who attended Orthopaedic Department Hospital Universiti Sains Malaysia
(HUSM), Kubang Kerian between January to December 2015 which have been surgically
debrided. Patients who fulfilled the criteria were randomized to receive treatment with
Hydrocyn™ Aqua (n = 30) or CASOS (n = 30) with daily dressing for 2 weeks. Outcome
measures include demographic data, size of wounds, wound bed scoring and complications
at baseline and at 2 weeks.
Results:
Wound reduction percentage after 2 weeks of treatment with Hydrocyn™ Aqua and CASOS
showed no difference in both groups (p= 0.9). The wound bed scoring at 2 weeks of treatment
showed no difference for both treatments. (p= 0.09) There was no adverse reactions recorded
for both groups.
Conclusion:
There is no significant difference for the efficacy of Hydrocyn™ Aqua compared to the
commercially available super oxidized solution in the treatment of diabetic foot ulcers. |
|---|